GlassScriptPhysician profile
Mona Sazgar
NPI 1215909486
$222,117.23
in general payments reported to CMS, 2019-2025
15 companies · $15K in 2025
The $15K reported for 2025 was more than what 93% of Epilepsy providers received nationally (typical 2025 total: $366).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36K · 2020: $31K · 2021: $23K · 2022: $71K · 2023: $23K · 2024: $23K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Honoraria: $25K · Food and Beverage: $5,166 · Travel and Lodging: $4,060.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,145.00 |
| Honoraria | $24,650.00 |
| Food and Beverage | $5,165.68 |
| Travel and Lodging | $4,060.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $75,782.64 | 2019-2025 | Briviact, Nayzilam, Fintepla |
| Sk Life Science, INC. | $60,205.22 | 2021-2025 | Xcopri |
| Eisai INC. | $44,079.40 | 2019-2022 | |
| Neurelis, INC. | $36,778.19 | 2020-2025 | Valtoco |
| Neuropace, INC. | $2,727.44 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $656.13 | 2024-2025 | |
| Sunovion Pharmaceuticals INC. | $646.15 | 2019-2022 | |
| Aquestive Therapeutics, INC. | $545.00 | 2021-2022 | |
| Livanova USA, INC. | $295.17 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $248.83 | 2023-2024 | Fycompa |
| Greenwich Biosciences, INC. | $145.00 | 2019 | |
| Travere Therapeutics, INC. | $8.06 | 2019-2022 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mona Sazgar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.